Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?

por Perretta, Fernando, Jaurretche, Sebastián
Publicado 2023

Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina

por Jaurretche, Sebastián, Antongiovanni, Norberto, Perretta, Fernando
Publicado 2017

Early Renal Involvement in a Girl with Classic Fabry Disease

por Perretta, Fernando, Antongiovanni, Norberto, Jaurretche, Sebastián
Publicado 2017

Major Organic Involvement in Women with Fabry Disease in Argentina

por Perretta, Fernando, Antongiovanni, Norberto, Jaurretche, Sebastián
Publicado 2018

High Lyso-Gb3 Plasma Levels Associated with Decreased miR-29 and miR-200 Urinary Excretion in Young Non-Albuminuric Male Patient with Classic Fabry Disease

por Jaurretche, Sebastián, Perez, Germán R., Venera, Graciela
Publicado 2019

Direct Correlation between Age at Diagnosis and Severity of Nephropathy in Fabry Disease Patients

por Jaurretche, Sebastián P. A., Antongiovanni, Norberto, Perretta, Fernando
Publicado 2019

Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry Disease Patients

por Jaurretche, Sebastián, Perez, Germán, Antongiovanni, Norberto, Perretta, Fernando, Venera, Graciela
Publicado 2019

Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists

por Jaurretche, Sebastián, Conde, Hernan, Gonzalez Schain, Ana, Ruiz, Franco, Sgro, Maria Victoria, Venera, Graciela
Publicado 2022